Table 1 TET1 expression correlates negatively with immune markers in many cancer types.

The correlation between TET1 expression and the score of the “top 20 immune signature” (defined in Fig. 2) were computed for all TCGA cancer cohorts. The name of the disease and the TCGA acronym, the Pearson correlation coefficient, the associated P value, and the number of cancer samples are indicated for each cohort.

Cancer typeTCGA cohortPearsonPNumber of samples
Ovarian serous cystadenocarcinomaOV−0.582.1 × 10−29307
Glioblastoma multiformeGBM−0.567.4 × 10−15166
SarcomaSARC−0.509.6 × 10−18263
Brain lower grade gliomaLGG−0.461.0 × 10−28530
Uterine carcinosarcomaUCS−0.445.7 × 10−457
Lung adenocarcinomaLUAD−0.419.0 × 10−23517
MesotheliomaMESO−0.416.9 × 10−587
Thyroid carcinomaTHCA−0.395.6 × 10−20509
CholangiocarcinomaCHOL−0.382.1 × 10−236
Uterine corpus endometrial carcinomaUCEC−0.369.1 × 10−7177
Skin cutaneous melanomaSKCM−0.361.1 × 10−15472
Kidney renal papillary cell carcinomaKIRP−0.334.9 × 10−9291
Uveal melanomaUVM−0.324.0 × 10−380
Lung squamous cell carcinomaLUSC−0.324.3 × 10−13501
Pheochromocytoma and paragangliomaPCPG−0.312.2 × 10−5184
Testicular germ cell tumorsTGCT−0.284.0 × 10−4156
ThymomaTHYM−0.282.1 × 10−3120
Adrenocortical carcinomaACC−0.252.9 × 10−279
Prostate adenocarcinomaPRAD−0.249.6 × 10−8498
Head and neck squamous cell carcinomaHNSC−0.183.0 × 10−5522
Kidney chromophobeKICH−0.171.8 × 10−166
Cervical and endocervical cancersCESC−0.132.0 × 10−2306
Bladder urothelial carcinomaBLCA−0.097.6 × 10−2408
Stomach adenocarcinomaSTAD−0.062.1 × 10−1415
Kidney renal clear cell carcinomaKIRC−0.026.2 × 10−1534
Liver hepatocellular carcinomaLIHC0.026.8 × 10−1373
Colon adenocarcinomaCOAD0.036.8 × 10−1191
Esophageal carcinomaESCA0.046.2 × 10−1185
Rectum adenocarcinomaREAD0.047.1 × 10−172
Pancreatic adenocarcinomaPAAD0.199.7 × 10−3179